Recruiting

Pharmacogenomic Testing

Sponsor:

University of Chicago

Code:

NCT01280825

Conditions

Patients Undergoing Routine Health Care

Heart Diseases

Inflammatory Bowel Diseases

Autoimmune Disease

Inflammatory Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

Conditions

Patients Undergoing Routine Health Care

Heart Diseases

Inflammatory Bowel Diseases

Autoimmune Disease

Inflammatory Disease

Study ID

NCT01280825

Start date

Jan 14, 2011

Status verified date

Mar, 2026

Completion date

Dec 14, 2027

Anticipated

Primary completion date

Nov 14, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
  • Life expectancy of at least 3 years
  • Must be 18 years or older
  • Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
  • Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:

  • Patients requiring specialized cardiology care
  • Patients with inflammatory bowel diseases
  • Patients with systemic autoimmune or inflammatory diseases
  • Patients requiring long-term oral anticoagulation
  • Patients with hepatitis C
  • Patients with non-metastatic cancer

Exclusion Criteria:

  • Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
  • Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
  • Inability to understand and give informed consent to participate.

Study Design

Enrollment

1200 participants

Anticipated

Interventions and Outcome Measures

Arms

Adult Patients

Adults receiving health care at the University of Chicago Medical Center.

Primary outcome measure

  • Feasibility of incorporating pharmacogenomic testing into routine medical care [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

1200 Patients Project Study Team

(773) 834-1759cpt1200@uchicago.edu

Cancer Clinical Trials Office

1-855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Locations

University of Chicago Medical Center

Recruiting

Chicago, Illinois, United States, 60637

More Information

Sponsor

University of Chicago

Last update posted

Mar 4, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Chicago on 2026-03-04.